LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 451

Search options

  1. Book ; Online: Chapter 4 Obesity Is a Disease

    Martin, William P / Le Roux, Carel

    2022  

    Keywords Diseases & disorders ; Obesity; disease
    Language English
    Size 1 electronic resource (6 pages)
    Publisher Springer Nature
    Document type Book ; Online
    Note English
    HBZ-ID HT030374774
    ISBN 9783030833985 ; 3030833984
    Database ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  2. Article ; Online: Treatment of obesity with medications binding the glucagon-like peptide 1 receptor: what is the current state of play?

    Le Roux, Carel / Mondoh, Alvin

    Expert opinion on pharmacotherapy

    2024  Volume 25, Issue 2, Page(s) 131–138

    Abstract: Introduction: Obesity, marked by abnormal fat accumulation, poses significant health risks, necessitating effective therapeutic interventions. The focus of this review is to elucidate the importance of glucagon-like peptide 1 (GLP-1) receptor-binding ... ...

    Abstract Introduction: Obesity, marked by abnormal fat accumulation, poses significant health risks, necessitating effective therapeutic interventions. The focus of this review is to elucidate the importance of glucagon-like peptide 1 (GLP-1) receptor-binding medications in addressing obesity-related health deteriorations.
    Areas covered: Exploring the mechanisms, efficacy, and safety profiles, this review comprehensively assesses medications selectively or non-selectively binding the GLP-1 receptor for obesity treatment. A meticulous analysis of phase 2 and phase 3 data positions retatrutide, CagriSema, survudotide, tirzepatide, semaglutide, and liraglutide in order of effectiveness. While showcasing their efficacy and safety, the review acknowledges the ongoing phase 3 studies, highlighting the need for further exploration of contraindications, dosage, and potential adverse effects to inform personalized treatment decisions.
    Expert opinion: The ongoing anticipation of long-term benefits, particularly sustained weight loss and cardiovascular outcomes, underscores the significance of future treatment algorithms for addressing the disease of obesity.
    MeSH term(s) Humans ; Hypoglycemic Agents/therapeutic use ; Diabetes Mellitus, Type 2/drug therapy ; Glucagon-Like Peptide-1 Receptor/therapeutic use ; Obesity/drug therapy ; Liraglutide/adverse effects
    Chemical Substances Hypoglycemic Agents ; Glucagon-Like Peptide-1 Receptor ; Liraglutide (839I73S42A)
    Language English
    Publishing date 2024-02-02
    Publishing country England
    Document type Review ; Journal Article
    ZDB-ID 2001535-5
    ISSN 1744-7666 ; 1465-6566
    ISSN (online) 1744-7666
    ISSN 1465-6566
    DOI 10.1080/14656566.2024.2311731
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5130: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Hypothalamic control of body fat mass by food intake: The key to understanding why obesity should be treated as a disease.

    Purnell, Jonathan Q / le Roux, Carel W

    Diabetes, obesity & metabolism

    2024  Volume 26 Suppl 2, Page(s) 3–12

    Abstract: Background: Hypothalamic centres have been recognized to play a central role in body weight regulation for nearly 70 years.: Aims: In this review, we will explore the current undersanding of the role the hypothalamus plays in controlling food intake ... ...

    Abstract Background: Hypothalamic centres have been recognized to play a central role in body weight regulation for nearly 70 years.
    Aims: In this review, we will explore the current undersanding of the role the hypothalamus plays in controlling food intake behaviours.
    Materials and methods: Review of relevant literature from PubMed searches and review article citations.
    Results: Beginning with autopsy studies showing destructive hypothalamic lesions in patients manifesting hyperphagia and rapid weight gain, followed by animal lesioning studies pinpointing adjacent hypothalamic sites as the 'satiety' centre and the 'feeding' centre of the brain, the neurocircuitry that governs our body weight is now understood to consist of a complex, interconnected network, including the hypothalamus and extending to cortical sites, reward centres and brainstem. Neurons in these sites receive afferent signals from the gastrointestinal tract and adipose tissue indicating food availability, calorie content, as well as body fat mass.
    Discussion: Integration of these complex signals leads to modulation of the two prime effector systems that defend a body fat mass set point: food intake and energy expenditure.
    Conclusion: Understanding the hypothalamic control of food intake forms the foundation for understanding and managing obesity as a chronic disease.
    MeSH term(s) Animals ; Humans ; Hypothalamus/physiology ; Obesity/metabolism ; Body Weight ; Adipose Tissue/metabolism ; Eating/physiology ; Energy Metabolism
    Language English
    Publishing date 2024-02-14
    Publishing country England
    Document type Review ; Journal Article
    ZDB-ID 1454944-x
    ISSN 1463-1326 ; 1462-8902
    ISSN (online) 1463-1326
    ISSN 1462-8902
    DOI 10.1111/dom.15478
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5442: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Biography: Carel le Roux.

    le Roux, Carel W

    Obesity surgery

    2020  Volume 30, Issue 6, Page(s) 2074–2075

    Language English
    Publishing date 2020-04-20
    Publishing country United States
    Document type Editorial
    ZDB-ID 1070827-3
    ISSN 1708-0428 ; 0960-8923
    ISSN (online) 1708-0428
    ISSN 0960-8923
    DOI 10.1007/s11695-020-04618-w
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3381: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: COVID-19 alters thinking and management in metabolic diseases.

    le Roux, Carel W

    Nature reviews. Endocrinology

    2020  Volume 17, Issue 2, Page(s) 71–72

    MeSH term(s) Air Pressure ; Autopsy ; Body Mass Index ; COVID-19/complications ; COVID-19/epidemiology ; COVID-19/pathology ; COVID-19/therapy ; Cause of Death ; Comorbidity ; Delivery of Health Care/methods ; Delivery of Health Care/organization & administration ; Delivery of Health Care/standards ; Endothelium, Vascular/pathology ; Endothelium, Vascular/virology ; Humans ; Lung/blood supply ; Lung/pathology ; Lung/virology ; Metabolic Diseases/complications ; Metabolic Diseases/epidemiology ; Metabolic Diseases/pathology ; Metabolic Diseases/therapy ; Neovascularization, Pathologic/mortality ; Neovascularization, Pathologic/pathology ; Neovascularization, Pathologic/virology ; Pandemics ; Pneumonia, Viral/complications ; Pneumonia, Viral/epidemiology ; Pneumonia, Viral/therapy ; Pulmonary Embolism/mortality ; Pulmonary Embolism/pathology ; Pulmonary Embolism/therapy ; Pulmonary Embolism/virology ; Respiration, Artificial/methods ; Respiration, Artificial/standards ; Respiratory Distress Syndrome/epidemiology ; Respiratory Distress Syndrome/pathology ; Respiratory Distress Syndrome/therapy ; Respiratory Distress Syndrome/virology ; Risk Factors ; SARS-CoV-2/physiology
    Language English
    Publishing date 2020-11-25
    Publishing country England
    Document type Journal Article
    ZDB-ID 2489381-X
    ISSN 1759-5037 ; 1759-5029
    ISSN (online) 1759-5037
    ISSN 1759-5029
    DOI 10.1038/s41574-020-00449-y
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6336: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MG 93: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Long-term weight outcomes in patients treated with liraglutide 3.0 mg in real-world clinical practice.

    Grannell, Andrew / Al-Najim, Werd / le Roux, Carel

    Clinical obesity

    2023  Volume 14, Issue 1, Page(s) e12622

    Abstract: Long-term weight outcomes reflect the success of obesity treatment. Weight regain during treatment for obesity is a biologically maladaptive response that can be considered a central feature of the disease. This phenomenon has been well documented in ... ...

    Abstract Long-term weight outcomes reflect the success of obesity treatment. Weight regain during treatment for obesity is a biologically maladaptive response that can be considered a central feature of the disease. This phenomenon has been well documented in patients treated with lifestyle changes and bariatric surgery. In patients treated with liraglutide 3.0 mg this has been documented in randomized control trials, but real-world analysis is lacking. The aim of this retrospective observational study was to explore the long-term weight outcomes in patients treated with liraglutide 3.0 mg in a real-world clinical practice. The association between body composition changes and weight outcomes was also explored. The study included 25 patients treated with multi-modal care that included liraglutide 3.0 mg over a period of 78 weeks. Body composition was examined via dual x-ray absorptiometry at 16 and 32 weeks, with body weight captured up until 78 weeks for all patients. Weight loss (R
    MeSH term(s) Humans ; Hypoglycemic Agents/therapeutic use ; Liraglutide/therapeutic use ; Obesity/drug therapy ; Weight Gain ; Weight Loss ; Retrospective Studies
    Chemical Substances Hypoglycemic Agents ; Liraglutide (839I73S42A)
    Language English
    Publishing date 2023-08-24
    Publishing country England
    Document type Observational Study ; Journal Article
    ZDB-ID 2625816-X
    ISSN 1758-8111 ; 1758-8103
    ISSN (online) 1758-8111
    ISSN 1758-8103
    DOI 10.1111/cob.12622
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6918: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: A review of the evidence on cardiovascular outcomes from obesity treatment.

    Abdul Wahab, Roshaida / le Roux, Carel W

    Obesity Pillars (Online)

    2023  Volume 7, Page(s) 100071

    Abstract: Background: Obesity is a chronic disease with a myriad of complications including cardiovascular disease. There is a growing interest to examine if obesity treatment is associated with cardiovascular outcomes.: Methods: In this narrative review, we ... ...

    Abstract Background: Obesity is a chronic disease with a myriad of complications including cardiovascular disease. There is a growing interest to examine if obesity treatment is associated with cardiovascular outcomes.
    Methods: In this narrative review, we focused on randomized controlled trials (RCT) with cardiovascular outcomes (CVO) from lifestyle intervention, bariatric surgery, glucagon-like peptide-1 analogues (GLP-1a) and other pharmacotherapy. Additionally, we provide a comprehensive look into the RCT of sodium glucose cotransporter 2 inhibitors (SGLT2i) and CVO in obesity, while also summarizing several ongoing randomized cardiovascular outcome controlled trials for the pharmacological treatment of obesity.
    Results: To date, the results from the randomized controlled trials supported the association between obesity treatment and cardiovascular outcomes. Studies have large sample sizes, conducted over long duration, with the majority demonstrating superiority in primary cardiovascular outcome end points compared to placebo.
    Conclusion: Future data from several ongoing anti-obesity medications cardiovascular outcome trials such as SELECT, SURPASS, SUMMIT and SURMOUNT-MMO hold promises. Further studies are warranted to investigate the long term cardiovascular outcomes following lifestyle intervention and bariatric surgery.
    Language English
    Publishing date 2023-05-20
    Publishing country United States
    Document type Journal Article ; Review
    ISSN 2667-3681
    ISSN (online) 2667-3681
    DOI 10.1016/j.obpill.2023.100071
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  8. Article: Weight loss to disrupt type 2 diabetes.

    Alsaqaaby, Moath S / le Roux, Carel W

    Diabetology international

    2023  Volume 14, Issue 3, Page(s) 217–223

    Abstract: Obesity is now recognised as a disease associated with significant morbidity and mortality. One of the most common metabolic complications of obesity is type 2 diabetes, because the two disease share similar pathophysiology. Weight loss is known to ... ...

    Abstract Obesity is now recognised as a disease associated with significant morbidity and mortality. One of the most common metabolic complications of obesity is type 2 diabetes, because the two disease share similar pathophysiology. Weight loss is known to ameliorate the metabolic abnormalities underlying type 2 diabetes and improve glycemic control. A 15% or greater total body weight loss (TBWL) in patients with type 2 diabetes will have a disease-modifying effect, a result that is incomparable with other hypoglycemic-lowering interventions. Moreover, in patients with diabetes and obesity, weight loss exerts benefits beyond glycemic control and improves cardiometabolic disease risk factors and well-being. We review evidence supporting the role of intentional weight loss in managing type 2 diabetes. We suggest that many people with type 2 diabetes would benefit from an additional weight-based approach to managing their diabetes. Therefore, we proposed a weight-based treatment goal for patients with type 2 diabetes and obesity.
    Language English
    Publishing date 2023-04-04
    Publishing country Japan
    Document type Journal Article ; Review
    ZDB-ID 2574501-3
    ISSN 2190-1686 ; 2190-1678
    ISSN (online) 2190-1686
    ISSN 2190-1678
    DOI 10.1007/s13340-023-00626-0
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: Pharmacotherapy before and after bariatric surgery.

    Alabduljabbar, Khaled / le Roux, Carel W

    Metabolism: clinical and experimental

    2023  Volume 148, Page(s) 155692

    Abstract: Diabetes is a chronic disease that affects a vast number of individuals globally, and without optimal treatment, can lead to significant health complications. Moreover, obesity is another chronic disease with several complications, which includes type 2 ... ...

    Abstract Diabetes is a chronic disease that affects a vast number of individuals globally, and without optimal treatment, can lead to significant health complications. Moreover, obesity is another chronic disease with several complications, which includes type 2 diabetes. Bariatric surgery is a viable long-term choice for managing diseases such as obesity and type 2 diabetes. However, the impact of pharmacotherapy before and after surgery remains unclear. In this review, we assessed the use of pharmacotherapy in patients with obesity with or without diabetes before and after bariatric surgery, focusing on weight loss, glycemic control, and the risk of postoperative complications. We showed that anti-obesity medication has become increasingly important in managing obesity and type 2 diabetes, both before and after bariatric surgery. The use of preoperative pharmacotherapy can optimize patients for surgery and reduce perioperative complications. Meanwhile, postoperative pharmacotherapy can maximize weight loss, improve metabolic outcomes, and lower the risk of weight regain. Medications such as sodium-glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide 1 (GLP-1) receptor agonists, and combination therapies, are now very effective for treating obesity and type 2 diabetes mellitus. However, optimal timing, duration, and which combinations of pharmacotherapy to use with bariatric surgery remain unclear. Additionally, the long-term safety and efficacy of these treatments should be assessed. Integrating pharmacotherapy with bariatric surgery is a promising approach to managing obesity and type 2 diabetes, providing patients with additional options for achieving sustainable weight loss and improving their metabolic health.
    Language English
    Publishing date 2023-09-18
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 80230-x
    ISSN 1532-8600 ; 0026-0495
    ISSN (online) 1532-8600
    ISSN 0026-0495
    DOI 10.1016/j.metabol.2023.155692
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uc I Zs.316: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Book: Controversies in obesity

    Haslam, David W. / Sharma, Arya M. / Le Roux, Carel W.

    2014  

    Author's details David W. Haslam ; Arya M. Sharma ; Carel W. le Roux ed
    Keywords Obesity
    Language English
    Size XIV, 306 S. : : Ill.
    Publisher Springer
    Publishing place London u.a.
    Publishing country Great Britain
    Document type Book
    HBZ-ID HT018140578
    ISBN 978-1-4471-2833-5 ; 9781447128342 ; 1-4471-2833-8 ; 1447128346
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    2014 A 343 available for loan (reading room) Lesesaal EG

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top